Business Wire

Gurobi Announces New “Gurobi Alliance” Program to Maximize Success for Customers and Partners

21.10.2021 16:00:00 EEST | Business Wire | Press release

Share

Gurobi Optimization, LLC – which produces the world’s fastest mathematical optimization solver, the Gurobi Optimizer – today announced the availability of the Gurobi Alliance, a new partner program providing exclusive communication, training, product, sales and marketing resources to partners in order to support and accelerate their delivery of high-performance, reliable results. The Gurobi Alliance program is designed to enhance Gurobi partners’ go-to-market strategies and help their customers leverage the expertise only a Gurobi partner can offer.

Across all industries, businesses are looking to accelerate revenue growth, drive demand and boost innovation, all while reducing risks and upfront investments. To do this successfully, they must have access to expert-backed programs and resources that help them establish, nurture and expand their relationships with customers.

With the introduction of this new program, Gurobi partners can leverage the dedicated people, resources and benefits they need to build and deliver successful customer solutions. Benefits and resources include:

  • Preferred pricing on licenses for application development or internal use
  • Access to on-demand technical training
  • Access to experts in the channel business, including development and marketing
  • Marketing, sales, and support programs to reach new customers and build awareness and drive demand

The Gurobi Alliance Program enables partners by leveraging a new partner portal that provides easy access to deal registrations, lead sharing and partner tools. Partners will have access to virtual trainings and enablement sessions. The program incorporates a tiered approach with escalating benefits including preferred discounts, bespoke marketing campaigns and access to industry experts.

Gurobi partners who join the Gurobi Alliance program can choose the engagement model and level that best fits their business. This includes the Service Engagement Model – which is designed for companies that provide services to customers, such as consulting, training and implementation related to Gurobi Optimizer – as well as the Solution Engagement Model – which is designed for independent software vendors and other companies that integrate the Gurobi Optimizer into their own product offerings.

“Paired with Gurobi’s best-of-breed solver, our new Gurobi Alliance partner program enables customers to amplify their development of successful solutions, meet customer demands and reach peak success,” said Dr. Ed Rothberg, CEO, Gurobi. “We’re proud to work with companies who are constantly on the cusp of innovation. With these new tools and resources, our partners and customers will be able to access the support they need to continuously grow and thrive in new directions.”

“It’s essential for companies to maintain and expand customer relationships, and a big part of that is meeting their demand for new and improved solutions,” said Silvana Quintero, Director of Ecosystem Marketing, Gurobi. “With access to tools like on-demand technical training, Gurobi partners will now receive extensive, crucial support throughout each stage of business development.”

For more information about the Gurobi Alliance partner program, please visit
https://www.gurobi.com/gurobi-alliance/overview/

About Gurobi Optimization

Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.

Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nell-Marie Colman
Director of Content
colman@gurobi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release

Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye